Antibodies against high‐risk human papillomavirus proteins as markers for noncervical HPV ‐related cancers in a Black South African population, according to HIV status
International Journal of Cancer · 15.07.2024 · 155 (2) · 251-260
DOI: 10.1002/ijc.34919 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 05.04.2024. Verfasst von Mwiza Gideon Singini und 6 weiteren Autor:innen. Beteiligte Einrichtung: International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France. Hauptthemen laut MEDLINE: Papillomavirus Infections, Antibodies, Viral, Oncogene Proteins, Viral, HIV Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: World Health Organization, Centre International de Recherche sur le Cancer.
Abstract (Originalsprache)
Human papillomavirus (HPV) proteins may elicit antibody responses in the process toward HPV‐related malignancy. However, HPV seroepidemiology in noncervical HPV‐related cancers remains poorly understood, particularly in populations with a high prevalence of human immunodeficiency virus (HIV). Using a glutathione S‐transferase‐based multiplex serology assay, antibodies against E6, E7 and L1 proteins of HPV16 and HPV18 were measured in sera of 535 cases of noncervical HPV‐related cancers (anal ( n = 104), vulval ( n = 211), vaginal ( n = 49), penile ( n = 37) and oropharyngeal ( n = 134)) and 6651 non‐infection‐related cancer controls, from the Johannesburg Cancer Study that recruited Black South African with newly diagnosed cancer between 1995 and 2016. Logistic and Poisson regression models were used to calculate adjusted odds ratios (aOR) and prevalence ratios (aPR) and 95% confidence intervals (CI) in cases versus controls. HPV16 E6 was more strongly associated with noncervical HPV‐related cancers than HPV16 L1 or E7, or HPV18 proteins: anal (females (HPV16 E6 aOR = 11.50;95%CI:6.0–22.2), males (aOR = 10.12;95%CI:4.9–20.8), vulval (aOR = 11.69;95%CI:7.9–17.2), vaginal (aOR = 10.26;95%CI:5.0–21), penile (aOR = 18.95;95%CI:8.9–40), and oropharyngeal (females (aOR = 8.95;95%CI:2.9–27.5), males (aOR = 3.49;95%CI:1.8–7.0)) cancers. HPV16‐E6 seropositivity ranged from 24.0% to 35.1% in anal, vulval, vaginal and penile cancer but was significantly lower (11.2%) in oropharyngeal cancer. After adjustment for HIV, prevalence of which increased from 22.2% in 1995–2005 to 54.1% in 2010–2016, HPV16 E6 seropositivity increased by period of diagnosis (aPR for 2010–2016 vs. 1995–2006 = 1.84;95%CI:1.1–3.0). Assuming HPV16 E6 seroprevalence reflects HPV attributable fraction, the proportion of certain noncervical‐HPV‐related cancers caused by HPV is increasing over time in South Africa. This is expected to be driven by the increasing influence of HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- International Agency for Research on Cancer (IARC/WHO), Early Detection, Prevention and Infections Branch, Lyon, France.
- National Cancer Registry, National Institute for Communicable Diseases a Division of the National Health Laboratory Service, Johannesburg, South Africa.
- School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
- South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.
- Center for Primary Health Care and Equity, School of Population Health, University of New South Wales Sydney, Sydney, New South Wales, Australia.
- Menzies Center of Health Policy, School of Public Health, University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Mazvita Muchengeti, Gary M Clifford
Förderung
- World Health Organization
- Centre International de Recherche sur le Cancer
Zitieren
APA
Singini, M. G., Muchengeti, M., Sitas, F., Chen, W. C., Combes, J. D., Waterboer, T., & Clifford, G. M. (2024). Antibodies against high‐risk human papillomavirus proteins as markers for noncervical HPV ‐related cancers in a Black South African population, according to HIV status. International Journal of Cancer, 155(2), 251-260. https://doi.org/10.1002/ijc.34919
Vancouver
Singini MG, Muchengeti M, Sitas F, Chen WC, Combes JD, Waterboer T, et al. Antibodies against high‐risk human papillomavirus proteins as markers for noncervical HPV ‐related cancers in a Black South African population, according to HIV status. International Journal of Cancer. 2024;155(2):251-260. doi:10.1002/ijc.34919
BibTeX
@article{Singini2024,
author = {Singini, Mwiza Gideon and Muchengeti, Mazvita and Sitas, Freddy and Chen, Wenlong Carl and Combes, Jean-Damien and Waterboer, Tim and Clifford, Gary M},
title = {Antibodies against high‐risk human papillomavirus proteins as markers for noncervical HPV ‐related cancers in a Black South African population, according to HIV status},
journal = {International Journal of Cancer},
year = {2024},
volume = {155},
number = {2},
pages = {251--260},
doi = {10.1002/ijc.34919}
}
EUVIMED